travoprost


Also found in: Wikipedia.

travoprost

 [trav´o-prost]
a synthetic prostaglandin analogue used in the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; administered topically to the conjunctiva.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

travoprost

A PROSTAGLANDIN analogue drug used in eye drops to control intraocular pressure in open angle GLAUCOMA. A brand name is Travatan.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

prostaglandin analogues 

Drugs used in the treatment of open-angle glaucoma or ocular hypertension. At specific dosages they lower the intraocular pressure (IOP), supposedly by increasing the outflow of aqueous humour via the uveoscleral pathway. Common agents include latanoprost, travoprost, bimatoprost (a synthetic prostamide structurally related to prostaglandin) and unoprostone isopropyl. Bimatoprost reduces IOP by increasing the uveoscleral outflow as well as the trabecular outflow.
Millodot: Dictionary of Optometry and Visual Science, 7th edition. © 2009 Butterworth-Heinemann
References in periodicals archive ?
OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.
The company's earlier stage assets include OTX-TIC, an extended-delivery intracameral travoprost implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases.
Ocular Therapeutix announced topline results from the first pivotal Phase 3 clinical trial of OTX-TP, an intracanalicular insert that delivers a preservative-free formulation of the drug travoprost for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Sustained effect of travoprost on diurnal and nocturnal intraocular pressure.
In this study, LayerBio's proprietary intracameral extended-release formulation of the glaucoma drug travoprost is shown to lower intraocular pressure to therapeutic levels for longer than six months.
IOP of the OD remained consistently above 50 mmHg with medications provided (i.e., travoprost, timolol, brinzolamide, brimonidine tartrate, and mannitol 20%).
The currently prescribed PGAs in our region are bimatoprost 0.01% (with BAK 0.02%), latanoprost 0.005% (with BAK 0.02%), travoprost 0.004% (with 0.001% polyquad), and tafluprost 0.0015% (preservative-free).
Later in 2014, Kucukevcilioglu and coworkers (2) described deepening of the upper eyelid sulcus in other PA, such as Latanoprost and Travoprost. Other studies describe different side effects of PA, such as conjunctival hyperemia, elongation and darkening of eyelashes, induced iris darkening, and periocular skin pigmentation (3-5).
Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
and prostaglandin analogs such as latanoprost, travoprost are playing an increasingly important role in the first-line therapy of glaucoma [6,8] The ocular hypotensive effect of once daily 0.5% timolol ranges from 17% to 28% which overlaps with that of twice daily timolol.